Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baxter Spins Off Drug Business To Focus On Devices, Anesthesia & Nutrition Products

This article was originally published in The Gray Sheet

Executive Summary

Kidney dialysis and biosurgery will be two major focus points for a newly refined Baxter after it spins off its biopharmaceuticals business, as planned for mid-2015.

You may also be interested in...

Joe Almeida Tapped As CEO Of Baxter

Former Covidien CEO José (Joe) Almeida has been appointed CEO of Baxter as the company zeroes in on its device businesses.

People Briefs: JenaValve CEO; Ortho-Clinical Changes; Baxter CFOs

JenaValve Technology names David Drachman as CEO. Ortho-Clinical Diagnostics makes executive changes following split from J&J. Baxter plans a CFO switch when it completes its biopharmaceutical company spinoff next year. More people news.

Baxter Buys Gambro For $4 Billion To Round Out Dialysis Device Lineup

Deal builds on Baxter’s home peritoneal dialysis-focused business by adding a suite of products for hemodialysis in the clinic, including Gambro’s Artis and AK 96 systems.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts